India, May 8 -- This week's biotech roundup features the FDA's path forward for Atara's tab-cel, Arvinas' first-in-class PROTAC approval, and Incyte's Jakafi XR securing a regulatory nod. The week also saw Novartis announcing a site closure, Roche striking a $750 million PathAI deal, and Angelini agreeing to buy Catalyst for $4.1 billion. On the clinical front, Aptevo, Cytokinetics, Viridian, and Mirium all reported positive trial data across oncology, cardiology, ophthalmology, and rare liver disease, respectively.
Let's take a closer look at the details.
FDA Approvals & Rejections
Atara Biotherapeutics Updates FDA Path for Tab-cel Following CRL
Atara Biotherapeutics, Inc. (ATRA) announced that following a Type A meeting with the FDA r...